Empagliflozin bioavailability study in healthy volunteers

Phase 1, randomised, open-label trial of empagliflozin (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 3 days and Maximum measured concentration of the analyte in plasma at 3 days. Started May 2025; status: completed.